Immuron Limited Sponsored ADR IMRN 深 滬
已收盤 06-18 16:00:00 美东时间
1.06
-0.010
-0.93%
華盛通- 最 高1.07
- 今 開1.07
- 成交量 8589股
- 最 低 1.036
- 昨 收 1.07
- 總市值 865.63万
- 52周最高 2.39
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 0.6765
- 委 比 -46.55%
- 總股本 816.63万
- 歷史最高 28.99
- 量 比 0.26
- 振 幅 3.18%
- 歷史最低 0.6765
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immuron Says No Undisclosed News Behind Share Price Spike
Immuron Limited ( ($AU:IMC) ) has shared an announcement. Immuron Limited has r...
05-28 11:08
Immuron shares are trading higher after the company reported a year-over-year increase in its Q3 sales results.
Immuron shares are trading higher after the company reported a year-over-year i...
04-17 23:46
Immuron Q3 sales rise 16% to A$1.5M
Immuron reported third-quarter global sales of A$1.5 million, up 16% from the prior comparative period, while year-to-date sales through March 2026 rose 7% to A$5.7 million. In the US, Q3 sales came i...
04-17 19:34
Immuron Double Digit 3Q Sales Growth
Immuron Limited reported Q3 sales growth for Travelan® with a 16% increase globally and 15% in Australia, driven by digital marketing and store expansion. U.S. sales rose 1% despite currency challenges, while Canada saw a 82% quarterly increase but a 65% YTD decline. The company highlights Travelan® as an immune supplement targeting gastrointestinal pathogens and emphasizes its platform technology for developing orally active antibodies.
04-17 10:00
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
Immuron Limited's CEO, Steven Lydeamore, is presenting at the Coffee Microcaps Conference on March 5, 2026. Immuron, an Australian biopharmaceutical company, focuses on developing orally delivered polyclonal antibodies for infectious diseases. Its product Travelan® is an oral immunotherapy to prevent travelers’ diarrhea and is approved in Australia, Canada, and the U.S. as a dietary supplement. IMM-529, another product, targets recurrent Clostrid...
03-05 11:00
Immuron HY26 net loss narrows 22.9% to AUD 1.9 million
Immuron HY26 net loss narrows 22.9% to AUD 1.9 million Immuron reported HY26 revenue from ordinary activities of AUD 4.2 million, up 4.8%, and a loss after tax attributable to shareholders of AUD 1.9 million, down 22.9%, for the six months ended 31 December 2025. Net tangible assets were 3.94 cents
03-02 19:10
Immuron H1 EPS $(0.01), Same YoY, Sales $4.184M Up From $3.994M YoY
Immuron (NASDAQ:IMRN) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $4.184 million in sales this quarter. This is a 4.76 percent increase over
02-25 21:26
BRIEF-Immuron Reports Hy26 Results And Strategic Reset
BRIEF-Immuron Reports Hy26 Results And Strategic Reset Feb 25 (Reuters) - Immuron Ltd IMC.AX : IMMURON REPORTS HY26 RESULTS AND STRATEGIC RESET IMMURON LTD: TAKEN A STRATEGIC DECISION TO PURSUE PARTNERSHIPS TO FUND PROGRESS OF TRAVELAN AND IMM-529 CLINICAL PROGRAMS Source text: ID:nGNX5F39D5 Furthe
02-25 19:26
Immuron reports 1H results
Immuron press release (IMRN): 1H record sales of A$4.2 million, up 5% on HY25. EPS of -A$0.70 More on Immuron Immuron Limited (IMRN) Presents at Emerging Growth Conference 89 - Slideshow Seeking Alpha...
02-25 19:14
Immuron Reports Continued Sales Growth
Immuron Limited reported H1 sales growth of Travelan® and ProIBS® across key markets. Global H1 sales reached AUD$4.2 million, up 5% YoY, with Australia leading at AUD$3.3 million (+13%) and the U.S. at AUD$0.9 million (+17%). Canada saw Q2 sales surge 191% after a slow start. ProIBS® launched in Australia ahead of schedule and will expand in Canada, targeting increased consumer awareness. The company attributes growth to marketing efforts, new s...
01-19 11:00
